Please use this identifier to cite or link to this item:
Title: Biodegradable polymers as a noncoding miRNA nanocarrier for multiple targeting therapy of human hepatocellular carcinoma
Authors: Yang, Chengbin
Yin, Ming-jie
Xu, Gaixia
Lin, Wei-Jen
Chen, Jiajie
Zhang, Yinling
Feng, Tao
Huang, Peng
Chen, Chih-Kuang
Yong, Ken-Tye
Keywords: Engineering::Electrical and electronic engineering
Issue Date: 2019
Source: Yang, C., Yin, M., Xu, G., Lin, W., Chen, J., Zhang, Y., Feng, T., Huang, P., Chen, C. & Yong, K. (2019). Biodegradable polymers as a noncoding miRNA nanocarrier for multiple targeting therapy of human hepatocellular carcinoma. Advanced Healthcare Materials, 8(8), 1801318-.
Project: 11235100003
NEWRI SF20140901
Journal: Advanced Healthcare Materials
Abstract: Therapeutic strategy based on the restoration of tumor suppressor-microRNAs (miRNAs) is a promising approach for cancer therapy, but the low delivery efficiency of miRNA remains a huge hurdle due to the lack of safe and efficient nonviral carriers. In this work, with the use of newly developed PEGylated biodegradable charged polyester-based vectors (PEG-BCPVs) as the carrier, the miR26a and miR122 codelivering therapeutic strategy (PEG-BCPVs/miR26a/miR122 as the delivery formulation) is successfully developed for efficient treatment of human hepatocellular carcinoma (HCC). In vitro study results show that PEG-BCPVs are capable of effectively facilitating miRNA cellular uptake via a cell endocytosis pathway. Consequently, the restoration of miR26a and miR122 remarkably inhibit the cell growth, migration, invasion, colony formation, and induced apoptosis of HepG2 cells. More importantly, the chemosensitivity of HepG2 to anticancer drug is also considerably enhanced. After treatment with the PEG-BCPV-based miRNA delivery system, the expression of the multiple targeted genes corresponding to miR26a and miR122 in HepG2 cells is greatly downregulated. Accordingly, the newly developed miRNA restoration therapeutic strategy via biodegradable PEG-BCPVs as the carrier should be a promising modality for combating HCC.
ISSN: 2192-2640
DOI: 10.1002/adhm.201801318
Rights: © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:EEE Journal Articles

Page view(s)

Updated on Jan 22, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.